Overview

A Dose Range Finding Study to Evaluate the Efficacy and Safety of AZD9668 Administered Orally at Three Dose Levels to Patients With Chronic Obstructive Pulmonary Disease (COPD) on Treatment With Tiotropium

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

The primary objective is to evaluate the dose-response relationship and efficacy of AZD9668 at 3 dose levels compared with placebo in symptomatic COPD patients by assessing effects on lung function and symptoms of COPD.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Tiotropium Bromide